Secondary leukaemia and myelodysplasia after autografting for lymphoma: is the transplant to blame?

Leukemia & Lymphoma
D W Milligan

Abstract

Haemopoietic stem cell autografting is becoming a standard part of the therapeutic repertoire for salvage of relapsed lymphoma patients. Over the last five years or so a number of studies have identified that such patients are at high risk of developing secondary acute myeloid leukaemia (AML) or myelodysplastic syndromes (MDS). The actuarial risks have been estimated to be up to 18% in some series. More recently, studies from France and the EBMT suggest that in Registries containing large numbers of transplanted patients the risks are lower and are of the order of 3-5% at five years. Cytogenetic examination of bone marrow cells taken pre-transplant may also show identical abnormalities to those found in the leukaemic clone after transplant indicating that in many instances the stem cell damage was caused by prior treatment. In addition, a report from the British National Lymphoma Investigation has identified that post-transplant MDS/AML was related to the total quantity of treatment received, with mustine being identified as a particular culprit. It thus seems probable that the additional stem cell insult offered by the transplant may be small although a factor which may increase the risk is the use of total body irradiation.

References

Sep 1, 1991·Blood Reviews·S Devereux
Jan 4, 1990·The New England Journal of Medicine·J M KaldorD Assouline
Dec 1, 1994·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·R M StoneA S Freedman
Mar 1, 1993·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J P MarolleauC Gisselbrecht
Apr 1, 1996·Hematology/oncology Clinics of North America·M J Thirman, R A Larson
Nov 1, 1996·British Journal of Haematology·R GovindarajanG Tricot
Oct 6, 1997·Bone Marrow Transplantation·S JagannathB Barlogie
Mar 21, 1998·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M J LaughlinJ J Vredenburgh
Jun 5, 1998·Bone Marrow Transplantation·B R MeisenbergL D Piro
Sep 11, 1998·Bone Marrow Transplantation·C S NeitzertJ Avery
Feb 2, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J ApostolidisA Z Rohatiner

❮ Previous
Next ❯

Citations

Jun 1, 2004·International Journal of Hematology·Debra L FriedmanH Joachim Deeg
Jan 28, 2006·Mayo Clinic Proceedings·David P Steensma, John M Bennett

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

CNS Lymphoma

In CNS lymphoma, cancerous cells from lymph tissues or other parts of the body form tumors in the brain and/or spinal cord. Here is the latest research on this rare non-Hodgkin lymphoma.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.